Objectives/Background The population of people who use drugs (PWUD) has the highest prevalence of hepatitis C virus (HCV) infections in Europe. PWUD are multimorbid patients who are difficult to integrate into existing healthcare systems. In our study, we evaluated the feasibility of providing HCV treatment within opioid maintenance treatment (OMT) programmes offering integrated primary care-based health services under one roof.
Objectives/Background The population of people who use drugs (PWUD) has the highest prevalence of hepatitis C virus (HCV) infections in Europe. PWUD are multimorbid patients who are difficult to integrate into existing healthcare systems. In our study, we evaluated the feasibility of providing HCV treatment within opioid maintenance treatment (OMT) programmes offering integrated primary care-based health services under one roof.
Methods We evaluated 66 charts of patients in four outpatient clinics (OMT) with HCV treatment (between 2002 and 2010). Fourteen of the patients were treated with heroin and nine patients had an HIV coinfection. Data on the socioeconomic characteristics and quality of life were assessed. We counted the number of consultations in the clinic to assess how much supportive care the patients needed.
Results Overall, 62% of all patients (41 out of 66) achieved a sustained virological response (SVR). A total of 84% of patients with genotype 3 achieved an SVR. Sixty-four percent of patients treated with heroin achieved an SVR. The majority of patients (71%) used illicit drugs during HCV treatment and over 80% were diagnosed with psychiatric comorbidities. Comparisons of patient characteristics according to SVR or non-SVR showed that a longer duration of OMT, more consultations per week during HCV treatment and poor self-reported physical condition were associated with non-SVR.
Conclusion
We conclude that offering HCV treatment in an integrated primary care-based setting with OMT and individualized use of different supporting strategies allows for treatment success rates in the population of PWUD that is comparable to the ones in the population of patients without drug use. Heroin maintenance treatment programmes offer a feasible and safe setting for providing HCV treatment. 
Introduction
Hepatitis C infections are widely spread in the population of former and current injecting drug users, causing significant morbidity and mortality among them [1, 2] . There are an estimated 170 million individuals worldwide carrying the hepatitis C virus (HCV) [1, 3] , and in the population of people who use drugs (PWUD), the estimated prevalence of HCV antibodies varies between 60 and 80% [4] . In Switzerland, PWUD show the highest prevalence of HCV infection [5] .
PWUDs are patients with high rates of psychiatric and somatic comorbidities, and multiple substance abuse is common. PWUD are a group of multimorbid patients who are known to be hard to reach and particularly difficult to integrate into existing healthcare systems. Even though treatment for HCV infection exists with rates of sustained virological response (SVR) in more than 50% of patients, the population of PWUD is rarely treated [6] . Studies have showed the feasibility of HCV treatment in this population [7] [8] [9] [10] , but eligibility remains low because patients with on-going illicit drug use, alcohol consumption, psychiatric comorbidities or HIV infection are often excluded from treatment.
Because of their complex needs, opioid-dependent patients are often treated in specialized, multidisciplinary opioid maintenance treatment (OMT) programmes. OMT programmes usually focus on addiction and psychiatric conditions, whereas physical conditions are neglected. In OMT programmes, patients might have on-site access to basic primary healthcare. For more specialized treatments, as HCV requires, they have to be referred to secondary or tertiary care specialists. In these off-site clinics, the complex medical and psychosocial conditions of PWUD and the anticipation of potential psychiatric side effects can act as a barrier to starting HCV treatment.
At the individual level, the main indication for hepatitis C treatment is to prevent end-stage liver disease and liver cancer. At the public health level, scaling up treatment uptake in this heavily affected population could contribute towards reducing the epidemic [11] . One way to achieve this could be to develop and provide appropriate integrated settings for this marginalized group of patients to enhance their eligibility for treatment uptake.
Arud runs four outpatient clinics for addiction medicine in Zurich, Switzerland, offering integrated primary carebased interdisciplinary health services all under one roof. In this setting, patients are being treated for their addiction as well as their psychiatric comorbidities. Opioid-dependent patients can be treated with methadone, buprenorphine, long-acting morphine and prescribed heroin, depending on their individual situation and needs. In each clinic, on-site primary medical care is available including infectious diseases specialist care for HCV and HIV assessment and treatment.
The objective of this study is to analyse the outcome of HCV treatments in the integrated primary care-based outpatient clinics providing HCV care for a population that is difficult to treat, including patients with on-going use of illicit drugs and alcohol and with psychiatric comorbidities. In addition, we aimed to investigate patient characteristics associated with HCV treatment outcome.
Methods

Study design and patient population
We carried out a retrospective chart review of all patients in the primary care-based outpatient clinics for addiction medicine with HCV treatment for the period from 2002 to 2010.
Psychiatrists and psychologists were responsible for substance abuse counselling including opioid substitution with methadone, buprenorphine and long-acting morphine. We also included patients who were treated with heroin in the heroin maintenance treatment (HMT) programme during the same period. Primary care specialists and internists provided comprehensive medical services throughout the study. The full-time staff in our outpatient clinics included nurses and social workers. According to stability and physical and mental well-being, the patients were seen by our clinic staff at different intervals from daily to at least once a week. With the exception of prescribed heroin, which has to be consumed daily at the clinic, patients were allowed to receive up to 6 take-home doses of the substitution medication per week. If required, our patients had access to a walk-in clinic at all times, with medical and psychiatric staff at their disposal. Internists and primary care specialists were responsible for HCV treatment. If necessary, they consulted with off-site hepatologists to discuss patient care issues. Specially trained nurses were involved in every consultation, providing medical and psychosocial support, side effect management and information about the disease and treatment.
All patients signed an informed consent form on the use of their anonymized data for this study.
Treatment protocol
All patients in OMT programmes with chronic hepatitis C (twice positive for HCV antibodies and HCV-RNA) were informed about the possibility of HCV treatment at our clinics. HCV treatment was offered to all interested patients who did not show any contraindications such as uncontrolled substance abuse, uncontrolled depression, psychosis or a severe concurrent medical disease. Importantly, reported illicit drug use (heroin, cocaine, cannabinoids or nonprescribed benzodiazepine) and/or intake of alcohol, injecting drug use or psychiatric comorbidities were not contraindications per se for the start of HCV treatment in our study. Patients who consumed substances were offered treatment as long as their consumption occurred in a controlled manner. Our definition of controlled substance use is consumption according to rules for safer use and in modest amounts so as not to impair adherence to treatment. We also included patients with HIV coinfections as well as patients on prescribed heroin.
Before starting HCV treatment, the patients underwent the following examinations: clinical examination by a psychiatrist, standard medical examination by an internist or a primary care specialist, an assessment of liver disease and a baseline blood test. HCV genotype and HCV-RNA (IU/ml) were quantified at baseline and an abdominal ultrasound was performed. A liver biopsy was not a prerequisite for treatment.
The HCV treatment and monitoring was carried out according to European Association for the Study of the Liver (EASL) guidelines with once weekly pegylated interferon a-2a (180 mg/week) or a-2b (1.5 mg/kg/week) plus weight-based ribavarin orally twice daily. The patients could inject the interferon at home or receive the injections at the clinic (either self-administered or administered by a nurse). Ribavarin was dispensed in daily doses and takehome doses were given as up to a month's supply depending on the individual condition of each patient.
In the first 4 weeks of HCV treatment, all patients attended the clinic at least once a week for assessment of haematological and liver parameters and clinical side effects. After the initial 4 weeks, they were invited to attend the clinic once weekly or more if needed. They could make an appointment or just drop in to see the internist, the nurse or the psychiatrist. In weeks 12, 24 and 48, and again 24 weeks after the end of treatment, consultations were mandatory to evaluate the treatment.
determine patient characteristics associated with treatment success.
The psychiatric comorbidities including the substance dependences were diagnosed by the psychiatrists and referred to the 'International Statistical Classification of Diseases and Related Health Problems' (ICD 10). Data on socioeconomic characteristics and quality of life were collected by means of a questionnaire. The data collection on socioeconomic characteristics included questions about the patient's current housing situation, that is whether they were living by themselves or with a partner, whether they had permanent accommodation or not and where they received their income from (employment, disability benefits or social welfare). The quality of life was assessed by a self-administered questionnaire asking about the current mental, physical and socioeconomic condition (good, moderate, poor). The patients were also asked to declare their use of illicit drugs and intake of alcohol. If they used illicit substances at least once during the HCV treatment, they were considered as positive for illicit drug use. In the same way, they were considered as patients who use injecting drugs during the HCV treatment if they injected substances at least once. The intake of alcohol was also asked by self-report (intake on regular basis = more than 50 g/week). The use of illicit substances and alcohol was asked before starting and during HCV treatment. We counted the number of consultations in the clinic to assess how much supportive care they needed.
Statistical analyses
Descriptive statistics were calculated for all variables and presented as median [interquartile range (IQR)] or frequency as appropriate. Patients were categorized into two groups according to their HCV treatment success (i.e. SVR and non-SVR). Nonparametric group comparisons were performed to test for differences in the distribution of patient characteristics. Multiple logistic regression analysis was used to further investigate the independent association between treatment success and patient characteristics. The final model included significant patient characteristics (e.g. P < 0.05) resulting from the bivariate analysis. To minimize confounding, sociodemographics as well as addiction-specific and infection-specific characteristics were included in the model, irrespective of the significance level. Goodness of fit of the final model was tested by applying the HosmerLemeshow test. A two-sided P-value of less than 0.05 was considered statistically significant. All statistical analyses were carried out using STATA for Windows (version 12.1; Stata Corp., College Station, Texas, USA).
Results
Population
Between 2002 and 2010, we initiated HCV treatment in 66 opioid-dependent patients (80% men) with a median (IQR) age of 40 (33.7-44. 2) years at the beginning of treatment. Overall, 50% (n = 33) of patients had genotype 3, 32% (n = 21) had genotype 1, 14% (n = 9) had genotype 4 and 4% (n = 3) had genotype 2. The baseline viral load was below 800 000 IU/ml in 41% (n = 27).
The median duration of OMT before HCV treatment was 24.5 months (IQR 8.6-77.2). In total, 36% (n = 24) of all patients had one and 32% (n = 21) had two or more additional substance abuse diagnoses (e.g. cocaine, benzodiazepine, cannabinoid or alcohol dependence). During HCV treatment, 70% (n = 45) of patients received opioid substitution treatment (OMT) with methadone, buprenorphine or morphine, 21% (n = 14) were treated with heroin and 9% (n = 7) were not substituted at all. Among all patients, 69% declared an active or former injection drug use. In total, 40% of all patients reported injecting drug use during HCV treatment. A majority of patients (77%) used illicit drugs, including injecting and noninjecting drugs, during HCV treatment. Twenty-one patients (32%) reported alcohol intake on a regular basis.
In the study population, psychiatric comorbidities were diagnosed in 83% (n = 54) and HIV coinfection in 11% (n = 7). The socioeconomic characteristics of the patients before the initiation of HCV treatment are shown in Table 1 .
HCV treatment outcome
Forty-one out of 66 patients (62%) achieved an SVR. In five patients without follow-up, a negative HCV-RNA was documented at the end of treatment. Therefore, among patients with available follow-up information required to assess SVR, an SVR of 67% (41 out of 61) was achieved.
Overall, 85% (28 out of 33) of patients with genotype 3 achieved an SVR, 33% (seven out of 21) with genotype 1, 67% (two out of three) with genotype 2 and 44% (four out of nine) with genotype 4. In bivariate analysis, there was a significant difference in SVR across genotypes (P < 0.001), which was mainly related to the SVR in genotype 3 (84%, 28 out of 33) in comparison with the 'non-3' genotypes with a composite SVR of 39.4% (13 out of 33).
Nine of the 14 patients with heroin treatment had genotype 3, two had genotype 4 and three had genotype 1. Overall, 64% (n = 9) of the patients treated with heroin achieved an SVR (eight with genotype 3, one with genotype 4).
In the group of HIV-coinfected patients (n = 7), three had genotype 3, three had genotype 1 and one had genotype 2. Out of the seven HIV-coinfected patients, 43% (n = 3) achieved an SVR.
Number of consultations, duration of treatment and reasons for treatment failure
During their treatment, 49% (n = 30) of patients were seen at our clinic at least once a week, 40% (n = 25) had a consultation at least every 2 weeks and only 11% (n = 7) had less than one consultation every 2 weeks (missing data in four cases).
In total, 45 patients received HCV treatment as intended in the protocol. Twenty-one patients had to terminate HCV treatment at an early stage, 15 of them because of medical reasons. Nine dropouts had a viral failure (two with breakthrough, seven nonresponders). In five cases, we had to stop the treatment at an early stage because of severe medical conditions (two because of anaemia, one because of leucopoenia, one because of severe loss of weight and diarrhoea and one because of Bartter-Schwarz syndrome). Nevertheless, these five patients achieved an SVR.
The reasons for dropout, treatment failure and outcome are shown in detail in Fig. 1 .
Patient factors for treatment success
Detailed bivariate comparisons of patient characteristics according to SVR status are listed in Table 2 . In addition to HCV genotype, a longer duration of OMT, more consultations per week and self-reported poor physical condition were associated with non-SVR. Illicit drug use, including injecting and noninjecting drugs, during HCV treatment was not associated with an SVR.
Longer OMT duration and nongenotype 3 remained independently associated with non-SVR in a multiple logistic regression model controlling for the following covariates: age, sex, number of consultations per week, self-reported physical health, heroin treatment, injecting drug use and illicit drug consumption and alcohol consumption during HCV treatment, HIV coinfection and number of additional substance abuse disorders. The corresponding adjusted odds ratios for OMT duration (per month) and nongenotype 3 for treatment failure were 1.04 (P = 0.016) and 39.4 (P = 0.010). A goodness of fit test of the final model did not show a violation of the regression assumptions.
There was a significant and inverse association between self-reported physical health categories (good, moderate, poor) and weekly number of consultations. The corresponding median (IQR) weekly consultations for good, moderate and poor self-reported physical health were as follows: 0.8 (0.7-1.4), 1.0 (0.6-1.3) and 1.5 (1.1-2.2) (P = 0.022 and 0.026 for the comparison between poor vs. moderate and poor vs. good physical health, respectively).
Discussion
In our study, we have shown the feasibility of providing HCV treatment successfully within an integrated primary care-based setting to a multimorbid population of individuals who use drugs. Overall, 62% of the patients achieved an SVR. The patients with HCV genotype 3, the most common genotype within the population of PWUD in Europe, achieved an SVR rate of 84%. A high percentage (over 80%) of the patients was diagnosed with a psychiatric comorbidity and 10% were coinfected with HIV. Despite OMT, over 70% of patients used illicit drugs (40% even using injecting drugs) during HCV treatment. In the group of patients with prescribed heroin, the SVR rate of 64% was comparable to the overall SVR rate. Thus, HCV treatment is also feasible in HMT.
Comparisons of patient characteristics according to SVR or non-SVR showed some significant factors for not achieving an SVR (non-SVR). Not surprisingly, the genotype 'nongenotype 3' was one of the factors. A longer duration of OMT, more consultations per week during HCV treatment and poor self-reported physical condition were also associated with non-SVR. In multivariable logistic regression analysis, only 'nongenotype 3' and a longer duration of OMT remained significantly associated with HCV treatment failure. We assume that a longer duration of OMT is an indicator of poorer psychosocial and physical condition and reduced stability. This instability could influence HCV treatment, for example by reducing the tolerability of side effects, leading to reduction of dosage of antiviral therapy, or by reducing adherence to the treatment. Notably, the ongoing illicit use of drugs, even injecting drug use, was not a factor for not achieving an SVR.
As we offered support according to individual needs, our patients claimed more supportive care and counselling than is recommended in treatment schedules for patients Primary care-based HCV treatment for PWUD Brunner et al. 1303
without drug use [12] . Almost half of the patients required, on average, one consultation per week during the whole HCV treatment. Around 40% of the patients needed a consultation every 2 weeks. On the one hand, the intensive integrated care is probably one of the reasons for the treatment success in this hard-to-reach population. In contrast, the observed correlation between self-reported physical health and number of consultations, both associated with treatment failure, also suggests a nonlinear association between the demand of care and non-SVR.
A main strength of our study is the inclusion of patients irrespective of on-going illicit drug use, intake of alcohol and psychiatric comorbidities. This population represents, in a realistic way, the difficult-to-treat population of multimorbid PWUD. A further strength is the inclusion of patients in HMT programmes, as this could be a possible setting to reach those patients and provide them with HCV treatment. We are aware of several limitations of our study. The retrospective analysis and the lack of a control group are the major limitations. Another limitation is the self-reported drug use. However, because the use of drug had no consequences for the patients, such as exclusion from HCV treatment or substitution therapy, we assume high validity of the data [13, 14] .
Our results correspond with other studies showing the feasibility of HCV treatment of PWUD with comparable SVR rates to patients without drug use in different settings [7] [8] [9] [10] [15] [16] [17] [18] [19] [20] [21] [22] . As we did in our study, they report that OMT with a multidisciplinary approach is a safe and successful opportunity to treat PWUD for HCV [18, [23] [24] [25] [26] [27] . However, in some of these studies, patients with active drug use and/or alcohol intake and/or HIV infection were excluded or not described in detail. Therefore, our study population indicates to a greater extent the multimorbid difficult-to-treat population of PWUD including patients in heroin treatment programmes. To our knowledge, there is only one published study on HCV treatment in heroin treatment programmes with a population of 21 patients [28] with SVR rates comparable to our small sample.
A main feature of our HCV treatment setting is the provision of healthcare services in an integrated primary care-based (all under one roof) setting. Primary carebased settings for HCV treatment for either patients without drug use or PWUD have rarely been described [29] [30] [31] . Hence, we present a relatively unique possible setting for HCV management in PWUD.
Integration of HCV treatment in OMT with primary care facilities seems to be a promising approach because if patients are referred to a specialized off-site clinic for HCV treatment, less than a third will attend [32] . An advantage of integrating HCV treatment in primary care is its low threshold service, which facilitates treatment uptake. Offering easily accessible HCV treatment means reaching more patients of the marginalized population of PWUD. Thus, the primary care setting is, in all likelihood, the most suitable setting to increase HCV treatment uptake in this hard-to-reach population.
There is increasing evidence that patients with chronic diseases such as heart failure and diabetes benefit from Relapse n = 9
Unknown n = 2
Et. Neg./lost to follow-up n = 5
Reasons for dropout and treatment failure. Et.Neg, end of treatment HCV-RNA negative, lost to follow-up. HCV, hepatitis C virus; SVR, sustained virological response.
integrated care models [33] [34] [35] . A strong primary carebased approach can improve quality of care by coordinated and integrated care in chronically ill patients. If we consider HCV infection as a chronic condition, an integrated primary care-based treatment would be the appropriate approach. A recent randomized-controlled trial of an integrated care intervention [36] reported a significantly higher HCV treatment eligibility compared with the standard care group, suggesting treatment expansion to underserved populations. These findings support our hypothesis that PWUD would benefit from such an approach.
We want to point out in particular the individualized and need-adapted approach we offered in our integrated setting. We offered as many consultations during the HCV treatment for supportive care as needed instead of predetermined appointments. To our knowledge, this is the first study to take into account the individualized support. In previous studies, the frequency of consultations Primary care-based HCV treatment for PWUD Brunner et al. 1305
was described as 'weekly', 'several times per week' or 'as needed' [18, 23, 25, 31, 37 ], but has not been integrated in the analyses so far.
The need-adapted approach in our setting implies more effort with more supportive care for the patients. Consultations on a need-based frequency during HCV treatment could improve the understanding of the treatment and therefore the handling of side effects for both the patient and the physician involved. This personalized support could help the patient complete the treatment. Perhaps the major advantage of our clinic is the emphasis on the low threshold to treatment and staff-patient relationships, as patients are well known by the staff. According to our findings with respect to the extensive support we provided to the patients, only a few stopped treatment early on because of personal reasons. There are only a few prospective studies with randomized control groups reviewing the effects of different support strategies on hepatitis C treatment outcomes in PWUD [38] .
Another aspect of our study we would like to point out is the potential impact of HCV treatment in the population of PWUD on public health. Mathematical modelling predicts that scaling up treatment uptake could have a positive impact on the prevalence of HCV and therefore reducing the risk of infection [39, 40] . As long as treatment rates, especially in the hard-to-reach population of PWUD, remain low, the new highly effective antiviral agents will have limited global impact. Thus, treatment settings that enhance treatment uptake might have the potential to affect public health by reducing the prevalence of HCV. Increasing the availability of treatment settings as described in our study could help scale up treatment uptake in PWUD.
The question of which is the most efficient and costeffective HCV treatment setting for a multimorbid collective of PWUD remains unanswered. Another question that has not been answered is whether our approach is as cost-effective as HCV treatment for PWUD is in general [41] .
We conclude that offering HCV treatment in an integrated primary care-based setting with OMT and individualized use of different supporting strategies allows for treatment success rates in the multimorbid population of PWUD that are comparable to the ones in the population of patients without drug use. Furthermore, HMT programmes offer a feasible and safe setting for providing HCV treatment.
The use of integrated primary care-based multidisciplinary management strategies for chronic care seems to be a promising way to optimize treatment uptake and the treatment itself in the underserved population of PWUD.
To enhance treatment uptake rates, more integrated primary care-based settings should be set up. Therefore, addiction treatment programmes with OMT should provide on-site HCV treatment for their patients.
